Patents Assigned to Institut National De La Sante et Da La Recherche Medicale
  • METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF MYELODYSPLASTIC SYNDROMES
    Publication number: 20170100378
    Abstract: The present invention provides methods and pharmaceutical compositions designed to intervene in this defective process and to promote or restore erythrocyte maturation in individuals suffering from a myelodysplastic syndrome. The methods involve maintaining the activity of GATA-1 by preventing sequestration of Hsp70 in the cytoplasm. Accordingly, it is an object of this invention to provide methods of restoring or increasing erythrocyte maturation in a subject suffering from a myelodysplastic syndrome by preventing proteolytic inactivation of GATA-1. In some embodiments, preventing is achieved by administering to the subject a compound that inhibits the XPO1 nuclear transporter.
    Type: Application
    Filed: June 9, 2015
    Publication date: April 13, 2017
    Applicant: INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DA LA RECHERCHE MÉDICALE)
    Inventor: Olivier HERMINE
  • Particles containing a growth factor, and uses thereof
    Patent number: 9238008
    Abstract: The present invention concerns particles containing at least one covalently cross-linked polysaccharide and at least one growth factor, a method of preparation, and uses thereof.
    Type: Grant
    Filed: March 5, 2012
    Date of Patent: January 19, 2016
    Assignees: Institut National de la Sante et da la Recherche Medicale (INSERM), Centre National de la Recherche Scientifique (CNRS), Universite de Rouen, Universite de Reims Champagne-Ardennes, Centre Hospitalier Universitaire de Rouen
    Inventors: Ebba Brakenhielm, Sébastien Banquet, Florence Edwards-Levy, Christian Thuillez
  • Live attenuated strains as a single dose vaccine against whooping cough
    Patent number: 9119804
    Abstract: A mutated Bordetella strain comprising at least a mutated ptx gene, a deleted or mutated dnt gene and a heterologous ampG gene is provided. The attenuated mutated Bordetella strain can be used in an immunogenic composition or a vaccine for the treatment or prevention of a Bordetella infection. Use of the attenuated Bordetella strain for the manufacture of a vaccine or immunogenic composition, as well as methods for protecting mammals against infection by Bordetella are also provided.
    Type: Grant
    Filed: March 7, 2007
    Date of Patent: September 1, 2015
    Assignees: Institut Pasteur de Lille, Institut National de la Sante et da la Recherche Medicale
    Inventors: Camille Locht, Nathalie Mielcarek, Anne-Sophie Debrie, Dominique Raze, Julie Bertout
  • Polypeptides having serotonin receptor activity (5HT5A), nucleic acids coding for these polypeptides and uses thereof
    Patent number: 5807691
    Abstract: The present invention concerns novel polypeptides designated 5HT5a having serotonin receptor activity, genetic material permitting their expression, any recombinant cell expressing said polypeptides and uses thereof.
    Type: Grant
    Filed: March 29, 1995
    Date of Patent: September 15, 1998
    Assignee: Institut National De La Sante et Da La Recherche Medicale
    Inventors: Nourdine Amlaiky, Ursula Boschert, Rene Hen, Jean-Luc Plassat